Ungarn - ungarsk - OGYÉI (Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézetről)

teva b.v. - kolisztimetát-nátrium -

Ungarn - ungarsk - OGYÉI (Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézetről)

teva b.v. - kolisztimetát-nátrium -

Ungarn - ungarsk - OGYÉI (Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézetről)

forest laboratories uk ltd. - kolisztimetát-nátrium -

Den europeiske union - ungarsk - EMA (European Medicines Agency)

teva b.v. - colistimethate nátrium - cisztás fibrózis - szisztémás antibakteriális szerek, - a colobreathe a pseudomonas aeruginosa okozta krónikus tüdőfertőzések kezelésére javallt cisztás fibrózisban szenvedő betegeknél, akiknek hat éves vagy idősebb. figyelembe kell venni hivatalos útmutató a megfelelő használatára az antibakteriális szerek.

Den europeiske union - ungarsk - EMA (European Medicines Agency)

pharmaxis europe limited - mannit - cisztás fibrózis - köhögés és hideg készítmények - a bronchitol cisztás fibrózis (cf) kezelésére javallt 18 éves és idősebb felnőtteknél, mint kiegészítő kezelés a legjobb minőségű ellátás érdekében.

Ungarn - ungarsk - OGYÉI (Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézetről)

mip pharma gmbh - cefazolint nátrium -

Ungarn - ungarsk - OGYÉI (Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézetről)

apta medica internacional d.o.o. - cefazolint -

USA - engelsk - NLM (National Library of Medicine)

x-gen pharmaceuticals, inc. - colistimethate (unii: dl2r53p963) (colistin - unii:z67x93hjg1) - colistin 150 mg in 2 ml - colistimethate for injection, usp is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. it is particularly indicated when the infection is caused by sensitive strains of pseudomonas aeruginosa. this antibiotic is not indicated for infections due to proteus or neisseria . colistimethate for injection, usp has proven clinically effective in treatment of infections due to the following gram-negative organisms: enterobacter aerogenes, escherichia coli, klebsiella pneumoniae and pseudomonas aeruginosa . colistimethate for injection, usp may be used to initiate therapy in serious infections that are suspected to be due to gram-negative organisms and in the treatment of infections due to susceptible gram-negative pathogenic bacilli. to reduce the development of drug-resistant bacteria and maintain the effectiveness of colistimethate for injection, usp and other antibacterial drugs, colistimethate for injection, usp should be used only to treat or

USA - engelsk - NLM (National Library of Medicine)

xellia pharmaceuticals aps - colistimethate (unii: dl2r53p963) (colistin - unii:z67x93hjg1) - colistin 150 mg in 2 ml - colistimethate for injection, usp is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. it is particularly indicated when the infection is caused by sensitive strains of pseudomonas aeruginosa. this antibiotic is not indicated for infections due to proteus or neisseria . colistimethate for injection, usp has proven clinically effective in treatment of infections due to the following gram-negative organisms: enterobacter aerogenes, escherichia coli, klebsiella pneumoniae and pseudomonas aeruginosa . colistimethate for injection, usp may be used to initiate therapy in serious infections that are suspected to be due to gram-negative organisms and in the treatment of infections due to susceptible gram-negative pathogenic bacilli. to reduce the development of drug-resistant bacteria and maintain the effectiveness of colistimethate for injection, usp and other antibacterial drugs, colistimethate for injection, usp should be used only to treat or

USA - engelsk - NLM (National Library of Medicine)

sagent pharmaceuticals - colistimethate sodium (unii: xw0e5ys77g) (colistimethate - unii:dl2r53p963) - colistin 150 mg in 2 ml - colistimethate for injection is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. it is particularly indicated when the infection is caused by sensitive strains of pseudomonas aeruginosa . this antibiotic is not indicated for infections due to proteus or neisseria . colistimethate for injection has proven clinically effective in treatment of infections due to the following gram-negative organisms: enterobacter aerogenes, escherichia coli, klebsiella pneumoniae and pseudomonas aeruginosa. colistimethate for injection may be used to initiate therapy in serious infections that are suspected to be due to gram-negative organisms and in the treatment of infections due to susceptible gram-negative pathogenic bacilli. to reduce the development of drug-resistant bacteria and maintain the effectiveness of colistimethate for injection and other antibacterial drugs, colistimethate for injection should be used only to treat or prevent infections that ar